Jehn, U.; Siam, S.; Wiening, V.; Pavenstädt, H.; Reuter, S.
Belatacept as a Treatment Option in Patients with Severe BK Polyomavirus Infection and High Immunological Risk—Walking a Tightrope between Viral Control and Prevention of Rejection. Viruses 2022, 14, 1005.
https://doi.org/10.3390/v14051005
AMA Style
Jehn U, Siam S, Wiening V, Pavenstädt H, Reuter S.
Belatacept as a Treatment Option in Patients with Severe BK Polyomavirus Infection and High Immunological Risk—Walking a Tightrope between Viral Control and Prevention of Rejection. Viruses. 2022; 14(5):1005.
https://doi.org/10.3390/v14051005
Chicago/Turabian Style
Jehn, Ulrich, Sami Siam, Vanessa Wiening, Hermann Pavenstädt, and Stefan Reuter.
2022. "Belatacept as a Treatment Option in Patients with Severe BK Polyomavirus Infection and High Immunological Risk—Walking a Tightrope between Viral Control and Prevention of Rejection" Viruses 14, no. 5: 1005.
https://doi.org/10.3390/v14051005
APA Style
Jehn, U., Siam, S., Wiening, V., Pavenstädt, H., & Reuter, S.
(2022). Belatacept as a Treatment Option in Patients with Severe BK Polyomavirus Infection and High Immunological Risk—Walking a Tightrope between Viral Control and Prevention of Rejection. Viruses, 14(5), 1005.
https://doi.org/10.3390/v14051005